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Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K: 
Short-term risk of death after treatment with nesiritide for 
decompensated heart failure: a pooled analysis of 
randomized controlled trials. JAMA 2005, 293:1900-1905 
[1]. 
Background 
Nesiritide improves symptoms in patients with acutely 
decompensated heart failure compared with placebo and 
appears to be safer than dobutamine. Its short-term safety 
relative to standard diuretic and vasodilator therapies is less 
clear. 
Methods 
Design: Pooled analysis of randomized controlled trials.  
Objective: To investigate the safety of nesiritide relative to 
noninotrope-based control therapies, primarily consisting of 
diuretics or vasodilators. 
Data sources: Primary reports of completed clinical trials 
as of December 2004 were obtained from the US Food and 
Drug Administration (FDA), the study sponsor (Scios Inc), a 
PubMed literature search using the terms nesiritide, clinical 
trials, and humans, and a manual search of annual 
meetings of 3 heart associations. 
Study selection: Of 12 randomized controlled trials 
evaluating nesiritide, 3 met all inclusion criteria: randomized 
double-blind study of patients with acutely decompensated 
heart failure, therapy administered as single infusion (> or 
=6 hours), inotrope not mandated as control, and reported 
30-day mortality. 
Data extraction: Data were extracted from FDA and 
sponsor documents and corroborated with published articles 
when available. Thirty-day survival was assessed by meta-
analysis using a fixed-effects model and time-dependent 
risk by Kaplan-Meier analysis with Cox proportional hazards 
regression modeling. Where deaths were described within a 
range of days after treatment, an extreme assumption was 
made favoring nesiritide over control therapy, an approach 
relevant to the time-dependent analyses. 
Results 
In the 3 trials, 485 patients were randomized to nesiritide 
and 377 to control therapy. Death within 30 days tended to 
occur more often among patients randomized to nesiritide 
therapy (35 [7.2%] of 485 vs 15 [4.0%] of 377 patients; risk 
ratio from meta-analysis, 1.74; 95% confidence interval [CI], 
0.97-3.12; P = .059; and hazard ratio after adjusting for 
study, 1.80; 95% CI, 0.98-3.31; P = .057).  
Conclusion 
Compared with noninotrope-based control therapy, 
nesiritide may be associated with an increased risk of death 
after treatment for acutely decompensated heart failure. The 
possibility of an increased risk of death should be 
investigated in a large-scale, adequately powered, 
controlled trial before routine use of nesiritide for acutely 
decompensated heart failure. 
Commentary 
In 2004, there were more than one million hospitalizations in 
the United States for congestive heart failure (CHF), and 
inpatient treatment for this condition accounts for as much 
as $35 billion in health care expenditures annually [2]. 
Standard treatments, such as diuretics, angiotensin 
converting enzyme (ACE) inhibitors, and digitalis, are not 
always successful in improving symptoms and may not 
improve survival. Accordingly, scientists and clinical 
investigators have been searching for improved agents for 
the treatment of acutely decompensated CHF. 
Nesiritide is a recombinant human B-type natriuretic peptide 
that increases intracellular cyclic-GMP in vascular smooth 
muscle cells, leading to smooth muscle relaxation, preload 
Page 1 of 2 
(page number not for citation purposes) Critical Care   Vol 10 No 3   Kapoor and Milbrandt 
and afterload reduction, and increased cardiac index in 
patients with CHF [2]. It is US FDA approved for the 
treatment of acutely decompensated CHF based on its 
ability to rapidly reduce the surrogate endpoints of dyspnea 
and left ventricular filling pressure. Two recent meta-
analyses raised concern that nesiritide might lead to 
worsening renal function [3] and increased mortality [1]. It is 
this latter study that we review in this journal club critique. 
Sackner-Bernstein and colleagues conducted a pooled 
analysis of short-term risk of death in three large 
randomized controlled trials of nesiritide in patients with 
acutely decompensated CHF. They found that treatment 
with nesiritide was associated with a 74% increased risk of 
death within 30 days, though this increase was marginally 
significant (p=0.059). The importance of the study in raising 
the awareness of the potential risks associated with 
nesiritide cannot be overstated. However, there are a few 
limitations to this study that deserve consideration.  
Because the authors wished to focus on nesiritide’s FDA 
approved indication (treatment of acutely decompensated 
CHF), this meta-analysis only considered the results of 
three of the twelve randomized controlled trials of nesiritide. 
The authors clearly establish their criteria for study 
selection, including complete 30-day follow-up, noninotrope-
based control therapies, and closed-label trial design. 
However, it would have been useful for the authors to have 
presented estimates of risk with and without the nine 
excluded studies, especially if these additional studies also 
highlight the potential for harm with the drug. While the 
three studies they examined were randomized trials, there 
were important differences among the treatment groups. 
The authors adjusted for these differences, but others have 
raised concerns about the adequacy of this adjustment 
[4,5]. Many of the subjects in the three trials received 
infusions of nesiritide that were on the high end of the 
approved range, raising the possibility that these higher 
infusion rates may have been responsible for the trend 
toward increased mortality. 
These limitations not withstanding, this meta-analysis raises 
serious concern about the use of nesiritide and highlights 
the potential risks of drugs that receive FDA approval based 
on surrogate endpoints as opposed to mortality. The 
controversy that this and other analyses have generated 
has been impressive [4-9], prompting an advisory panel 
review and a “Dear Healthcare Provider” letter in July 2005 
from the manufacturer, Scios. This letter stressed that the 
use of nesiritide should be strictly limited to patients 
presenting to the hospital with acutely decompensated CHF 
who have dyspnea at rest and that physicians should 
carefully consider the potential risk and benefits and the 
availability of alternative therapies. It goes on to state that 
the drug should not be used for intermittent outpatient “tune-
up” infusions, a common and expensive practice of 
unproven benefit [6]. 
To clear up the confusion, Scios is initiating a European 
registration trial: Evaluating Treatment with Nesiritide in 
Acute Decompensated Heart Failure (ETNA). The ETNA 
study will enroll at least 1,900 patients with acutely 
decompensated CHF in approximately 400 sites in Europe 
and Latin America. The first patient is expected to be 
enrolled sometime in 2006. The study will randomize 
patients to either nesiritide or placebo through a 24-72 hour 
infusion added to standard care. Importantly, ETNA will 
prospectively evaluate mortality (through 30 and 180 days) 
and re-hospitalizations and will also include a 
pharmacoeconomic analysis. 
Recommendation 
Until the results of ETNA are available, we cannot 
recommend the use of nesiritide for the treatment of acutely 
decompensated CHF outside the setting of clinical trials.  
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